Drugs / Donor-derived Natural Killer Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07256210 | May 2025 → Oct 2026 expected | T-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor-derived Natural Killer Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07256210 ↗ |
| Modality | Cell therapy | “mbIL21 ex vivo-expanded donor-derived NK-cell infusions” NCT07256210 ↗ |